Abbott Laboratories (XSWX:ABT) Operating Income: CHF6,159 Mil (TTM As of Mar. 2026)

What is Abbott Laboratories Operating Income?

Abbott Laboratories XSWX:ABT +1.33% 76 Operating Income is CHF6,159 Mil as of Mar. 2026. GuruFocus rates XSWX:ABT with a GF Score™ of 76/100 and a GF Value™ of CHF103.55.

Abbott Laboratories's Operating Income for the three months ended in Mar. 2026 was CHF1,059 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was CHF6,159 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Abbott Laboratories's Operating Income for the three months ended in Mar. 2026 was CHF1,059 Mil. Abbott Laboratories's Revenue for the three months ended in Mar. 2026 was CHF8,789 Mil. Therefore, Abbott Laboratories's Operating Margin % for the quarter that ended in Mar. 2026 was 12.05%.

Good Sign:

Abbott Laboratories operating margin is expanding. Margin expansion is usually a good sign.

Abbott Laboratories's 5-Year average Growth Rate for Operating Margin % was 0.20% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Abbott Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 was 5.18%. Abbott Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 48.93%.

Abbott Laboratories (XSWX:ABT) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Abbott Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	4235.676 * ( 1 - 25.67% )	/	( (51249.436	+	70329.51)	/ 2 )
=	3148.3779708	/	60789.473
=	5.18 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	69101.59	-	10728.665	-	( 7123.489	-	max(0, 13145.662	-	20716.212	+	7123.489	))
=	51249.436

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	86940.752	-	10997.006	-	( 5743.354	-	max(0, 14468.212	-	20082.448	+	5743.354	))
=	70329.51

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Abbott Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	5111.152	/	( ( (9416.17 + max(760.243, 0))	+	(9744.412 + max(969.166, 0)) )	/	2 )
=	5111.152	/	( ( 10176.413	+	10713.578 )	/	2 )
=	5111.152	/	10444.9955
=	48.93 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(6318.62	+	5170.287	+	0)	-	(10728.665	+	0	+	-0.0010000000002037)
=	760.243

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(6463.733	+	5502.44	+	-0.0010000000002037)	-	(10997.006	+	0	+	0)
=	969.166

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Abbott Laboratories's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	1058.919	/	8789.417
	=	12.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Abbott Laboratories Operating Income Related Terms

Abbott Laboratories Operating Income Historical Data

* Premium members only.

The historical data trend for Abbott Laboratories's Operating Income can be seen below:

Abbott Laboratories Operating Income Chart

Abbott Laboratories Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Operating Income

Get a 7-Day Free Trial

7,759.43

7,790.04

5,602.17

6,085.17

6,417.44

Abbott Laboratories Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Operating Income	Get a 7-Day Free Trial															1,495.94	1,668.69	1,637.58	1,793.82	1,058.92

76GF Score

Abbott Laboratories XSWX:ABT

Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Abbott Laboratories Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF6,159 Mil.

Frequently Asked Questions Learn more about Operating Income →

What does a Operating Income of CHF6,159 Mil mean?

Abbott Laboratories (XSWX:ABT) has a Operating Income of CHF6,159 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Abbott Laboratories and its competitors.

Is Abbott Laboratories' Operating Income too high?

Abbott Laboratories' current Operating Income is CHF6,159 Mil. Overall, Abbott Laboratories has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.

How does Abbott Laboratories' Operating Income compare to SYK and MDT?

Abbott Laboratories' Operating Income of CHF6,159 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Operating Income for a Medical Devices & Instruments company?

A good Operating Income depends on the Medical Devices & Instruments industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Operating Income mean?

A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Abbott Laboratories and its competitors. Abbott Laboratories's current Operating Income is CHF6,159 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Abbott Laboratories stock overvalued right now?

Abbott Laboratories (XSWX:ABT) has a current Operating Income of CHF6,159 Mil. The stock's GF Value™ is CHF103.55, compared to a current price of CHF76.00 — trading 26.6% below its estimated fair value. The current Operating Income is CHF6,159 Mil. Abbott Laboratories' overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Operating Income calculated?

Operating Income is calculated from a company's financial statements. For Abbott Laboratories (XSWX:ABT), the current Operating Income is CHF6,159 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbott Laboratories (XSWX:ABT) Overvalued in 2026?

Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued. The current stock price of CHF76.00 is trading 26.6% below its estimated GF Value™ of CHF103.55.

Key valuation signals for XSWX:ABT:

Operating Income: CHF6,159 Mil
GF Value™: CHF103.55 vs. price of CHF76.00 (26.6% below fair value)
GF Score™: 76/100

No single metric tells the full story. See the XSWX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abbott Laboratories Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies SYK MDT BSX EW GEHC DXCM STE ZBH PEN GMED XTER:SHL XAMS:PHIA SZSE:300760 XSWX:SOON LSE:SN.SHSE:688271 TSE:7733 PODD BRKR OCSE:DEMANT

Other Exchanges ABT:USA ABT:Peru ABT:Mexico 1ABT:Italy 0Q15:UK ABL:Germany ABT:Chile ABT:Canada ABTT34:Brazil ABL:Bulgaria ABT:Austria ABT:Argentina

Address 100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400

Website https://www.abbott.com

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

76GF Score

Get the complete analysis for XSWX:ABT

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF76.00

Price

CHF103.55

GF Value

View XSWX:ABT Analysis

See Operating Income data for all stocks →